---
sidebar_position: 9
---

# æ–‡ç» 9ï¼šA Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence

**English Title**: A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence

**ä¸­æ–‡æ¨™é¡Œ**: ç›£æ¸¬å’Œè©•ä¼°ç’°å¢ƒäººå·¥æ™ºèƒ½çš„å¯¦ç”¨è©¦é©—æ“ä½œæ–°æ‰‹å†Š
**PMID**: 40959192
**æœŸåˆŠ**: NEJM AI
**è©•åˆ†**: 9
**æ‡‰ç”¨é ˜åŸŸ**: é–€è¨º
**DOI**: https://doi.org/10.1056/aidbp2401267

---

## ğŸ“Œ ç¬¬ä¸€å¼µï¼šæ ¸å¿ƒè§€é»å¡

### ä¸»è¦ç™¼ç¾
å‰µæ–°çš„å¯¦ç”¨æ€§è©¦é©—æ¡†æ¶

### æ–‡ç»æ‘˜è¦ï¼ˆAbstractï¼‰
BACKGROUND: Ambient artificial intelligence (AI) offers the potential to reduce documentation burden and improve efficiency through clinical note generation. Widespread adoption, however, remains limited due to challenges in electronic health record (EHR) integration, coding compliance, and real-world evaluation. This study introduces a framework and protocols to design, monitor, and deploy ambient AI within routine care. METHODS: We launched an implementation phase to build technical workflows, establish governance, and inform a pragmatic randomized trial. A bidirectional governance model linked operations and research through multidisciplinary workgroups that incorporated the Systems Engineering Initiative for Patient Safety (SEIPS) framework. Integration into the EHR used Fast Healthcare Interoperability Resources (FHIR), and a real-time dashboard tracked utilization and documentation accuracy. To monitor drift, a difference-in-differences analysis was applied to three process metrics: time in notes, work outside work, and utilization. Audits of  RESULTS: Ambient AI utilization, measured as the proportion of eligible clinical notes completed using the system, had a weighted median of 65.4% (interquartile range, 50.6 to 84.0%). Iterative improvement cycles targeted task-specific adoption. A brief workflow issue related to a note template change initially reduced ICD-10 documentation accuracy from 79% (95% confidence interval [CI], 72 to 86%) to 35% (95% CI, 28 to 42%); accuracy returned to baseline after note template redesign and user training. The internally developed LLM coder achieved a strong correlation with professional coders (Pearson's r=0.97). The trial enrolled 66 providers across eight specialties, powered at 90% for the primary outcome of provider well-being. CONCLUSIONS: We provide a publicly available framework and protocols to help safely implement ambient AI in health care. Innovations include an embedded pragmatic trial design, human factors engineering, compliance-driven feedback loops, and real-time monitoring to support deployment, ensuring fidelity before initiation of the clinical trial. (Funded by the University of Wisconsin Hospital and Clinics and the National Institutes of Health Clinical and Translational Science Award; NIH/ NCATS UL1TR002737; ClinicalTrials.gov number, NCT06517082.).

### ä¸­æ–‡æ‘˜è¦
**èƒŒæ™¯**ï¼šç’°å¢ƒäººå·¥æ™ºèƒ½ï¼ˆAmbient AIï¼‰é€éè‡¨åºŠç­†è¨˜ç”Ÿæˆï¼Œæä¾›æ¸›è¼•æ–‡ä»¶è² æ“”å’Œæé«˜æ•ˆç‡çš„æ½›åŠ›ã€‚ç„¶è€Œï¼Œç”±æ–¼é›»å­å¥åº·è¨˜éŒ„ï¼ˆEHRï¼‰æ•´åˆã€ç·¨ç¢¼åˆè¦æ€§å’Œå¯¦éš›è©•ä¼°æ–¹é¢çš„æŒ‘æˆ°ï¼Œå»£æ³›æ¡ç”¨ä»ç„¶å—é™ã€‚æœ¬ç ”ç©¶ä»‹ç´¹äº†ä¸€å€‹æ¡†æ¶å’Œå”å®šï¼Œç”¨æ–¼åœ¨å¸¸è¦ç…§è­·ä¸­è¨­è¨ˆã€ç›£æ¸¬å’Œéƒ¨ç½²ç’°å¢ƒ AIã€‚**æ–¹æ³•**ï¼šæˆ‘å€‘å•Ÿå‹•äº†ä¸€å€‹å¯¦æ–½éšæ®µï¼Œä»¥å»ºç«‹æŠ€è¡“å·¥ä½œæµç¨‹ã€å»ºç«‹æ²»ç†æ©Ÿåˆ¶ï¼Œä¸¦ç‚ºå¯¦ç”¨æ€§éš¨æ©Ÿè©¦é©—æä¾›è³‡è¨Šã€‚é›™å‘æ²»ç†æ¨¡å‹é€éè·¨å­¸ç§‘å·¥ä½œå°çµ„é€£çµç‡Ÿé‹å’Œç ”ç©¶ï¼Œè©²å°çµ„ç´å…¥äº†ç—…äººå®‰å…¨ç³»çµ±å·¥ç¨‹å€¡è­°ï¼ˆSEIPSï¼‰æ¡†æ¶ã€‚æ•´åˆè‡³ EHR ä½¿ç”¨å¿«é€Ÿå¥åº·ç…§è­·äº’é€šè³‡æºï¼ˆFHIRï¼‰ï¼Œå³æ™‚å„€è¡¨æ¿è¿½è¹¤ä½¿ç”¨ç‡å’Œæ–‡ä»¶æº–ç¢ºæ€§ã€‚ç‚ºç›£æ¸¬åç§»ï¼Œå°ä¸‰å€‹æµç¨‹æŒ‡æ¨™æ‡‰ç”¨å·®ç•°ä¸­ä¹‹å·®ç•°åˆ†æï¼šç­†è¨˜æ™‚é–“ã€å·¥ä½œå¤–å·¥ä½œå’Œä½¿ç”¨ç‡ã€‚**çµæœ**ï¼šç’°å¢ƒ AI ä½¿ç”¨ç‡ï¼ˆä»¥ä½¿ç”¨ç³»çµ±å®Œæˆçš„åˆæ ¼è‡¨åºŠç­†è¨˜æ¯”ä¾‹è¡¡é‡ï¼‰çš„åŠ æ¬Šä¸­ä½æ•¸ç‚º 65.4%ï¼ˆå››åˆ†ä½è· 50.6 è‡³ 84.0%ï¼‰ã€‚åè¦†æ”¹é€²å¾ªç’°é‡å°ç‰¹å®šä»»å‹™çš„æ¡ç”¨ã€‚èˆ‡ç­†è¨˜æ¨¡æ¿è®Šæ›´ç›¸é—œçš„ç°¡çŸ­å·¥ä½œæµç¨‹å•é¡Œæœ€åˆå°‡ ICD-10 æ–‡ä»¶æº–ç¢ºç‡å¾ 79%ï¼ˆ95% ä¿¡è³´å€é–“ [CI]ï¼Œ72 è‡³ 86%ï¼‰é™è‡³ 35%ï¼ˆ95% CIï¼Œ28 è‡³ 42%ï¼‰ï¼›åœ¨ç­†è¨˜æ¨¡æ¿é‡æ–°è¨­è¨ˆå’Œä½¿ç”¨è€…åŸ¹è¨“å¾Œï¼Œæº–ç¢ºç‡æ¢å¾©è‡³åŸºç·šã€‚å…§éƒ¨é–‹ç™¼çš„ LLM ç·¨ç¢¼å™¨èˆ‡å°ˆæ¥­ç·¨ç¢¼å“¡é”æˆå¼·ç›¸é—œæ€§ï¼ˆPearson's r=0.97ï¼‰ã€‚è©¦é©—æ‹›å‹Ÿäº† 66 åè·¨å…«å€‹å°ˆç§‘çš„æä¾›è€…ï¼Œå°ä¸»è¦çµæœï¼ˆæä¾›è€…ç¦ç¥‰ï¼‰å…·æœ‰ 90% çš„çµ±è¨ˆæ•ˆåŠ›ã€‚**çµè«–**ï¼šæˆ‘å€‘æä¾›äº†å…¬é–‹å¯ç”¨çš„æ¡†æ¶å’Œå”å®šï¼Œä»¥å”åŠ©åœ¨é†«ç™‚ç…§è­·ä¸­å®‰å…¨å¯¦æ–½ç’°å¢ƒ AIã€‚å‰µæ–°åŒ…æ‹¬åµŒå…¥å¼å¯¦ç”¨æ€§è©¦é©—è¨­è¨ˆã€äººå› å·¥ç¨‹ã€åˆè¦æ€§é©…å‹•çš„å›é¥‹å¾ªç’°ï¼Œä»¥åŠæ”¯æŒéƒ¨ç½²çš„å³æ™‚ç›£æ¸¬ï¼Œç¢ºä¿åœ¨è‡¨åºŠè©¦é©—å•Ÿå‹•å‰çš„ä¿çœŸåº¦ã€‚ï¼ˆè³‡åŠ©ä¾†æºï¼šå¨æ–¯åº·è¾›å¤§å­¸é†«é™¢å’Œè¨ºæ‰€ä»¥åŠåœ‹å®¶è¡›ç”Ÿç ”ç©¶é™¢è‡¨åºŠå’Œè½‰è­¯ç§‘å­¸çï¼›NIH/ NCATS UL1TR002737ï¼›ClinicalTrials.gov ç·¨è™Ÿ NCT06517082ï¼‰ã€‚

### é—œéµæ•¸æ“š
- **ç ”ç©¶é¡å‹**: æœªåˆ†é¡
- **åœ‹å®¶/åœ°å€**: å¾…æŸ¥
- **ç™¼è¡¨å¹´ä»½**: å¾…æŸ¥
- **ROI æ•¸å€¼**: ç„¡æ•¸å€¼

### æ ¸å¿ƒå‰µæ–°é»
æœ¬ç ”ç©¶çš„ä¸»è¦å‰µæ–°åœ¨æ–¼ï¼šå‰µæ–°çš„å¯¦ç”¨æ€§è©¦é©—æ¡†æ¶

---

## âœï¸ ç¬¬äºŒå¼µï¼šParaphrase å¡

### ç ”ç©¶ç›®çš„èˆ‡æ–¹æ³•
æœ¬ç ”ç©¶èšç„¦æ–¼é–€è¨ºé ˜åŸŸï¼Œæ—¨åœ¨æ¢è¨ AI æŠ€è¡“åœ¨é†«ç™‚å ´æ™¯ä¸­çš„æ‡‰ç”¨ã€‚

### ä¸»è¦è²¢ç»
ç ”ç©¶æå‡ºäº†å‰µæ–°çš„å¯¦ç”¨æ€§è©¦é©—æ¡†æ¶ï¼Œç‚ºè‡¨åºŠå¯¦è¸æä¾›äº†æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚

### æŠ€è¡“ç‰¹é»
- æ‡‰ç”¨å ´æ™¯ï¼šé–€è¨º
- å‰µæ–°ç¨‹åº¦ï¼šè©•åˆ† 9/10
- æœŸåˆŠå½±éŸ¿ï¼šç™¼è¡¨æ–¼ NEJM AI

---

## â“ ç¬¬ä¸‰å¼µï¼šå•ç­”å¡

### Q1: é€™é …ç ”ç©¶è§£æ±ºäº†ä»€éº¼å•é¡Œï¼Ÿ
A: æœ¬ç ”ç©¶é‡å°é–€è¨ºé ˜åŸŸçš„æŒ‘æˆ°ï¼Œæå‡ºäº†åŸºæ–¼ AI çš„è§£æ±ºæ–¹æ¡ˆã€‚

### Q2: æ¡ç”¨äº†ä»€éº¼æŠ€è¡“æ–¹æ³•ï¼Ÿ
A: å‰µæ–°çš„å¯¦ç”¨æ€§è©¦é©—æ¡†æ¶

### Q3: ç ”ç©¶çš„ä¸»è¦æˆæœæ˜¯ä»€éº¼ï¼Ÿ
A: ç ”ç©¶ç²å¾—äº† 9 åˆ†çš„å°ˆå®¶è©•åˆ†ï¼Œè­‰æ˜äº†å…¶åœ¨é–€è¨ºé ˜åŸŸçš„æ‡‰ç”¨åƒ¹å€¼ã€‚

### Q4: æœ‰å“ªäº›å¯¦éš›æ‡‰ç”¨å ´æ™¯ï¼Ÿ
A: ä¸»è¦æ‡‰ç”¨æ–¼é–€è¨ºï¼Œå¯ç”¨æ–¼æ”¹å–„é†«ç™‚æœå‹™å“è³ªå’Œæ•ˆç‡ã€‚

---

## ğŸ¤” ç¬¬å››å¼µï¼šä¾‹å¤–å¡

### æ½›åœ¨é™åˆ¶
1. **ç ”ç©¶ç¯„åœ**: ç ”ç©¶è©•åˆ†ç‚º 9/10ï¼Œå¯èƒ½å­˜åœ¨æ”¹é€²ç©ºé–“
2. **åœ°å€å·®ç•°**: ç ”ç©¶ä¾†è‡ªå¾…æŸ¥ï¼Œå…¶ä»–åœ°å€é©ç”¨æ€§éœ€é©—è­‰
3. **ROI æ•¸æ“š**: ç„¡æ•¸å€¼ï¼Œç¶“æ¿Ÿæ•ˆç›Šè©•ä¼°å¯èƒ½ä¸å®Œæ•´

### éœ€è¦é€²ä¸€æ­¥æ¢è¨çš„å•é¡Œ
1. è©²æŠ€è¡“åœ¨ä¸åŒè¦æ¨¡é†«é™¢çš„é©ç”¨æ€§å¦‚ä½•ï¼Ÿ
2. é•·æœŸä½¿ç”¨çš„æ•ˆæœå’Œç©©å®šæ€§æ˜¯å¦ç¶“éé©—è­‰ï¼Ÿ
3. èˆ‡ç¾æœ‰ç³»çµ±æ•´åˆæ™‚å¯èƒ½é¢è‡¨å“ªäº›æŒ‘æˆ°ï¼Ÿ

### æ‰¹åˆ¤æ€§æ€è€ƒ
- **æŠ€è¡“æˆç†Ÿåº¦**: éœ€è¦è©•ä¼°å¾ç ”ç©¶åˆ°å¯¦éš›éƒ¨ç½²çš„è·é›¢
- **æˆæœ¬æ•ˆç›Š**: ç„¡æ•¸å€¼ï¼Œéœ€è¦æ›´è©³ç´°çš„ç¶“æ¿Ÿåˆ†æ
- **å€«ç†è€ƒé‡**: AI åœ¨é–€è¨ºæ‡‰ç”¨æ™‚çš„å€«ç†å’Œéš±ç§å•é¡Œ
- **å¯æ¨å»£æ€§**: ç ”ç©¶çµæœåœ¨å…¶ä»–é†«ç™‚å ´æ™¯çš„é©ç”¨æ€§

---

## ğŸ“š åƒè€ƒè³‡è¨Š
- **PMID**: [40959192](https://pubmed.ncbi.nlm.nih.gov/40959192/)
- **DOI**: https://doi.org/10.1056/aidbp2401267
- **æœŸåˆŠ**: NEJM AI
